Melane Sampson, Author at BioTuesdays

Developments

AACN journal publishes study showing benefits of ENvue’s feeding tube guidance platform

ENvue Medical (NASDAQ: FEED) has announced that Critical Care Nurse, the official journal of the American Association of Critical-Care Nurses (AACN), has published an independent, peer-reviewed study showing significant...

June 3, 2026

Feature

Siloton further unlocking the power of OCT imaging with a groundbreaking photonic chip

Closely held Siloton is developing a patented miniaturized medical imaging platform that combines photonic chips with optical coherence tomography (OCT) to detect and monitor a range of prevalent ophthalmic diseases...

June 2, 2026

Developments

Senzime launches new EMG sensor for anesthesia monitoring

Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...

June 1, 2026

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Executive Moves

Former FDA official Peter J. Pitts joins BrainStorm BoD

BrainStorm Cell Therapeutics (OTCQB: BCLI) has appointed former FDA associate commissioner, Peter J. Pitts, to its board of directors (BoD), effective immediately. Mr. Pitts is a globally recognized expert in healthcare...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Feature

Pacylex reshaping cancer treatment with a novel once-daily oral therapy

Closely held Pacylex Pharmaceuticals is developing a first-in-class oral cancer therapy with a novel, broad mechanism of action designed for refractory cancers as both a monotherapy and a future combination therapy.

May 26, 2026

Author - Melane Sampson

AACN journal publishes study showing benefits of ENvue’s feeding tube guidance platform

Siloton further unlocking the power of OCT imaging with a groundbreaking photonic chip

Senzime launches new EMG sensor for anesthesia monitoring

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

Former FDA official Peter J. Pitts joins BrainStorm BoD

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Kura reports compelling data from trial of FTI in solid tumors

Percheron secures pINN from WHO for investigational cancer therapy

Pacylex reshaping cancer treatment with a novel once-daily oral therapy

Subscribe